Faculty Collaboration Database

Beneficial actions of bevantolol on subendocardial blood flow and contractile function in ischemic myocardium. J Cardiovasc Pharmacol 1979;1(1):139-47

Date

01/01/1979

Pubmed ID

94375

DOI

10.1097/00005344-197901000-00013

Scopus ID

2-s2.0-0018703011 (requires institutional sign-in at Scopus site)   23 Citations

Abstract

The effect of a new cardioselective beta adrenergic antagonist, bevantolol (CI-775), on regional myocardial blood flow and contractile function distal to a severe flow-limiting stenosis of the left circumflex coronary artery was studied in open-chest dogs. Bevantolol (1 mg/kg, i.v.) or saline was administered 30 min after production of left circumflex stenosis sufficient to reduce resting coronary blood flow and contractile force approximately 40%. Regional myocardial blood flow and contractile force were measured with radiolabeled microspheres and Brodie-Walton strain gauge arches, respectively. No significant changes were observed in the saline-treated group. Following bevantolol treatment subendocardial blood flow (1.30 +/- 0.29 to 0.93 +/- 0.19 ml/min/g) and contractile force decreased (11.4 +/- 4.4%) significantly (p less than 0.05) in nonischemic myocardium. Subendocardial blood flow (0.59 +/- 0.14 to 0.81 +/- 0.14 ml/min/g) and contractile force increased (29.3 +/- 3.6%) significantly (p less than 0.05) in ischemic myocardium. These results suggest that bevantolol produces a favorable redistribution of flow to ischemic subendocardium. The increase in flow results in an improvement of contractile function in the ischemic region.

Author List

Gross GJ, Buck JD, Warltier DC, Hardman HF

MESH terms used to index this publication - Major topics in bold

Adrenergic beta-Antagonists
Animals
Coronary Circulation
Coronary Disease
Dogs
Female
Hemodynamics
Male
Myocardial Contraction
Propanolamines